Initiation of hepatitis B virus genome replication and production of infectious virus following delivery in HepG2 cells by novel recombinant baculovirus vector
One of the major problems in gaining further insight into hepatitis B virus (HBV)/host-cell interactions is to improve the existing cellular models for the study of HBV replication. The first objective of this study was to improve the system based on transduction of HepG2 cells with a recombinant baculovirus to study HBV replication. A new HBV recombinant baculovirus, Bac-HBV-1.1, in which the synthesis of pre-genomic RNA is driven by a strong mammalian promoter, was generated. Transduction with this new recombinant baculovirus led to higher levels of HBV replication in HepG2 cells compared with levels obtained with previously described baculovirus vectors. The initiation of a complete HBV DNA replication cycle in Bac-HBV-1.1-transduced HepG2 cells was shown by the presence of HBV replicative intermediates, including covalently closed circular DNA (cccDNA). Only low levels of cccDNA were detected in the nucleus of infected cells. Data showed that cccDNA resulted from the recycling of newly synthesized nucleocapsids and was bound to acetylated histones in a chromatin-like structure. HBV particles released into the supernatant of transduced HepG2 cells were infectious in differentiated HepaRG cells. Several Bac-HBV-1.1 baculoviruses containing HBV strains carrying mutations conferring resistance to lamivudine and/or adefovir were constructed. Phenotypic analysis of these mutants confirmed the results obtained with the transfection procedures. In conclusion, an improved cell-culture system was established for the transduction of replication-competent HBV genomes. This will be useful for future studies of the fitness of HBV mutants.
AllenM. I.,
DeslauriersM.,
AndrewsC. W.,
TipplesG. A.,
WaltersK. A.,
TyrrellD. L.,
BrownN.,
CondreayL. D.1998; Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27:1670–1677[CrossRef]
BrunelleM. N.,
JacquardA. C.,
PichoudC.,
DurantelD.,
Carrouee-DurantelS.,
VilleneuveJ. P.,
TrepoC.,
ZoulimF.2005; Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 41:1391–1398[CrossRef]
DelaneyW. E.IV,
IsomH. C.1998; Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus. Hepatology 28:1134–1146[CrossRef]
DelaneyW. E.IV,
MillerT. G.,
IsomH. C.1999; Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (−)- β -2′,3′-dideoxy-3′-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA. Antimicrob Agents Chemother 43:2017–2026
DelaneyW. E.IV,
YangH.,
WestlandC. E.,
DasK.,
ArnoldE.,
GibbsC. S.,
MillerM. D.,
XiongS.2003; The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 77:11833–11841[CrossRef]
DurantelD.,
Carrouee-DurantelS.,
Werle-LapostolleB.,
BrunelleM. N.,
PichoudC.,
TrepoC.,
ZoulimF.2004; A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus. Hepatology 40:855–864[CrossRef]
DurantelD.,
BrunelleM. N.,
GrosE.,
Carrouee-DurantelS.,
PichoudC.,
VilletS.,
TrepoC.,
ZoulimF.2005; Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing. J Clin Virol 34 (Suppl. 1:S34–S43[CrossRef]
GriponP.,
DiotC.,
ThezeN.,
FourelI.,
LorealO.,
BrechotC.,
Guguen-GuillouzoC.1988; Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide. J Virol 62:4136–4143
GriponP.,
RuminS.,
UrbanS.,
Le SeyecJ.,
GlaiseD.,
CannieI.,
GuyomardC.,
LucasJ.,
TrepoC.,
Guguen-GuillouzoC.2002; Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 99:15655–15660[CrossRef]
LaskenR. S.,
EgholmM.2003; Whole genome amplification: abundant supplies of DNA from precious samples or clinical specimens. Trends Biotechnol 21:531–535[CrossRef]
MarcellinP.,
ChangT. T.,
LimS. G.,
TongM. J.,
SievertW.,
ShiffmanM. L.,
JeffersL.,
GoodmanZ.,
WulfsohnM. S.other authors2003; Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348:808–816[CrossRef]
MargeridonS.,
DurantelS.,
CheminI.,
BarraudL.,
ZoulimF.,
TrépoC.,
KayA.2006; Rolling circle amplification technology for the study of HBV variants. J Clin Virol 36:S51–S52
NewboldJ. E.,
XinH.,
TenczaM.,
ShermanG.,
DeanJ.,
BowdenS.,
LocarniniS.1995; The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 69:3350–3357
PetersM. G.,
Hann HwH.,
MartinP.,
HeathcoteE. J.,
BuggischP.,
RubinR.,
BourliereM.,
KowdleyK.,
TrepoC.other authors2004; Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126:91–101[CrossRef]
PollicinoT.,
BelloniL.,
RaffaG.,
PediconiN.,
SquadritoG.,
RaimondoG.,
LevreroM.2006; Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 130:823–837[CrossRef]
QiX.,
XiongS.,
YangH.,
MillerM.,
DelaneyW. E.4th (2007; In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 12:355–362
RenS.,
NassalM.2001; Hepatitis B virus (HBV) virion and covalently closed circular DNA formation in primary tupaia hepatocytes and human hepatoma cell lines upon HBV genome transduction with replication-defective adenovirus vectors. J Virol 75:1104–1116[CrossRef]
SellsM. A.,
ChenM. L.,
AcsG.1987; Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A 84:1005–1009[CrossRef]
SunD.,
NassalM.2006; Stable HepG2- and Huh7-based human hepatoma cell lines for efficient regulated expression of infectious hepatitis B virus. J Hepatol 45:636–645[CrossRef]
TuttlemanJ. S.,
PourcelC.,
SummersJ.1986; Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 47:451–460[CrossRef]
VilletS.,
PichoudC.,
VilleneuveJ. P.,
TrepoC.,
ZoulimF.2006; Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 131:1253–1261[CrossRef]
VilletS.,
OllivetA.,
PichoudC.,
BarraudL.,
VilleneuveJ. P.,
TrepoC.,
ZoulimF.2007; Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 46:531–538[CrossRef]
Werle-LapostolleB.,
BowdenS.,
LocarniniS.,
WursthornK.,
PetersenJ.,
LauG.,
TrepoC.,
MarcellinP.,
GoodmanZ.other authors2004; Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126:1750–1758[CrossRef]
ZhuY.,
YamamotoT.,
CullenJ.,
SaputelliJ.,
AldrichC. E.,
MillerD. S.,
LitwinS.,
FurmanP. A.,
JilbertA. R.,
MasonW. S.2001; Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 75:311–322[CrossRef]
ZoulimF.2004; Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 64:1–15[CrossRef]
Initiation of hepatitis B virus genome replication and production of infectious virus following delivery in HepG2 cells by novel recombinant baculovirus vector